Assyro AI

Orange Book product · Brand (NDA)

XARTEMIS XR

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Brand (NDA)NDA 204031DISCN MALLINCKRODT INC

At a glance

Mar 11, 2014

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Mar 11, 2014

    12 yr 5 mo ago

  2. Today

  3. Patent 7976870 expires

    Listed method-of-use patent (U-1498) expiration.

    Jun 01, 2027

    in 1 yr

  4. Patent 8372432 expires

    Listed drug product patent expiration.

    Mar 11, 2029

    in 2 yr 9 mo

  5. Patent 8394408 expires

    Listed drug product patent expiration.

    Mar 11, 2029

    in 2 yr 9 mo

  6. Patent 8668929 expires

    Listed method-of-use patent (U-1499) expiration.

    Mar 11, 2029

    in 2 yr 9 mo

  7. Patent 8377453 expires

    Listed drug product patent expiration.

    Nov 19, 2029

    in 3 yr 6 mo

  8. Patent 8597681 expires

    Listed drug product patent expiration.

    Dec 21, 2030

    in 4 yr 7 mo

  9. Patent 8980319 expires

    Listed drug product patent expiration.

    Dec 21, 2030

    in 4 yr 7 mo

  10. Patent 8658631 expires

    Listed drug product patent expiration.

    May 16, 2032

    in 6 yr

  11. Patent 8741885 expires

    Listed drug product patent expiration.

    May 16, 2032

    in 6 yr

  12. Patent 8992975 expires

    Listed drug product patent expiration.

    May 16, 2032

    in 6 yr

  13. Patent 9050335 expires

    Listed drug product patent expiration.

    May 16, 2032

    in 6 yr

  14. Patent 9468636 expires

    Listed method-of-use patent (U-1499) expiration.

    May 16, 2032

    in 6 yr

Pharmaceutical detail

Active ingredient

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

Strength

325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Dosage form

TABLET, EXTENDED RELEASE

Route

ORAL

TE code

Not listed

Application

NDA 204031

Product number

001

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7976870Jun 01, 2027in 1 yr
U-1498
8372432Mar 11, 2029in 2 yr 9 mo
ProductU-1499
8394408Mar 11, 2029in 2 yr 9 mo
Product
8668929Mar 11, 2029in 2 yr 9 mo
U-1499
8377453Nov 19, 2029in 3 yr 6 mo
ProductU-1499
8597681Dec 21, 2030in 4 yr 7 mo
Product
8980319Dec 21, 2030in 4 yr 7 mo
Product
8658631May 16, 2032in 6 yr
Product
8741885May 16, 2032in 6 yr
ProductU-1499
8992975May 16, 2032in 6 yr
Product
9050335May 16, 2032in 6 yr
Product
9468636May 16, 2032in 6 yr
U-1499
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.